
Journal of molecular catalysis p. 7 - 17 (1994)
Update date:2022-07-30
Topics:
Ohkubo
Sagawa
Minamoto
The stereoselective oxidation of enantiomeric amines (R(+)- or S(-)-α-phenylethylamine, 2a or 2b) has been performed with the chiral iron(III) porphyrin complexes of 5,10,15,20-tetrakis [p-((-)-methylcarbamoyl)phenyl]porphyrin (Fe111ClTmenPP, 1a) and α,α,α,α-isomer of 5,10,15,20-tetrakis[o-((t-butyloxycarbonyl)-L(-)-alan inamino)p henyl] porphyrinato iron(III) chloride (Fe111ClTboc-AlaPP, 1b) in benzene at 25 °C. The reaction obeyed biphasic kinetics, and 1a showed higher activity and stereoselectivity rather than 1b. On the basis of the kinetic analysis of the racemic amine oxidation by meso-tetraphenylporphyrinato iron(III) chloride (Fe111ClTPP, 1c), the stereoselective molecular recognition of the enantiomeric 2a-b substrates by 1a or 1b was found in the ligation step for the formation of the bis-ligated Fe111(amine)2 complex (4) and in the reduction of the chiral complex of 4 to the iron (II) one (3) by 2a (not predominant) or 2b (predominant) in the outersphere contact region of the chiral complex; the extent of the stereoselection by 1a (possessing the chiral portion in the equatorial position for the porphyrin plane) or 1b (possessing the chiral portion in the axial position for the porphyrin plane) was higher in the reduction step or in the second ligation step, respectively.
View MoreContact:027-87677569
Address:Room 2203, yujingmingmen Buidling One, xiongchu Road, wuhan city, hubei province, China
Contact:+86-571-28186845
Address:Room 1224,Eastcom Mansion,398 Wensan Road,Hangzhou,310013 China
Hubei Danao Pharmaceutical Co.,Ltd.
website:http://www.danaopharm.com
Contact:+86-719-5251167
Address:Fandan Road,Danjiangkou,Hubei
Jinan Baozhao Pharmaceutical Co., Ltd
Contact:0086-531-86397156 82371858 82371868
Address:Huaneng Road, Jinan, Shandong ,China
Hangzhou Zhenghan Biological Technology Co., Ltd.
Contact:86-571-88781753
Address:liangzhu yuhang hangzhou city
Doi:10.1002/(sici)1099-0690(199910)1999:10<2593::aid-ejoc2593>3.0.co;2-c
(1999)Doi:10.1021/jm049828c
(2004)Doi:10.1016/S0040-4039(01)87980-6
(1969)Doi:10.3184/174751915X14304939994023
(2015)Doi:10.3762/bjoc.12.180
(2016)Doi:10.1016/S0022-328X(00)84857-3
(1978)